Patents Examined by Shafiqul Haq
  • Patent number: 11519860
    Abstract: An object of the present invention is to provide a kit, a method, and a reagent which prevent the problem of false positive due to nonspecific adsorption, suppress the increase in noise to be generated, and are capable of achieving high-precision measurement of a measurement target substance in a wide concentration range from a low concentration to a high concentration.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: December 6, 2022
    Assignee: FUJIFILM Corporation
    Inventors: Hiroyuki Chiku, Tomoaki Yoshioka, Kousuke Watanabe, Kazuhiro Hamada, Kouitsu Sasaki
  • Patent number: 11499967
    Abstract: The present invention relates to a specific protein marker and to a method for identifying the statistical distribution of protein stoichiometry. Novel specific protein markers and methods for their detection are needed in order to clarify important biological questions. This objective is established by means of a specific protein marker comprising two (separate) units, of which the first unit comprises a molecule for specifically binding to a protein and at least one chemically coupled molecule for binding to the second unit, and the second unit comprises a surface-modified nanoparticle, said surface-modified nanoparticle having a surface coating comprising at least one molecule for binding to the first unit.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: November 15, 2022
    Assignee: LEIBNIZ-INSTITUT FUER NEUE MATERIALIEN GEMEINNUETZIGE GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG
    Inventors: Niels De Jonge, Diana B. Peckys
  • Patent number: 11480577
    Abstract: Disclosed are methods for detecting remnant cancer cells in a tissue sample.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: October 25, 2022
    Assignee: INDICATOR SYSTEMS INTERNATIONAL, INC.
    Inventors: Gerald F. Swiss, John V. Fante, Robert M. Moriarty, Richard J. Pariza
  • Patent number: 11474116
    Abstract: The present invention inter alia provides a method, and use thereof, of predicting CV complications such as AMI, ACS, stroke, and CV death by determining the concentrations of at least one ceramide of Group A and at least one ceramide of Group B in a biological sample and comparing those concentrations to a control. Finding a decreased concentration of at least one Group A ceramide and an increased concentration of at least one Group B ceramide indicates that the subject has an increased risk of developing one or more CV complications. Also provided are a newly identified subset of ceramide molecules, labelled versions thereof, and kits and compositions comprising the same for use in predicting and/or diagnosing CV complications.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: October 18, 2022
    Assignee: ZORA BIOSCIENCES, OY
    Inventor: Reijo Laaksonen
  • Patent number: 11448642
    Abstract: The invention relates to a method for determining whether a test compound can counteract malodour from a sulphur odorant. The method includes contacting the test compound and the sulphur odorant with an olfactory receptor OR4E2, and comparing the binding of the OR4E2 to the sulphur odorant, or the activity of the OR4E2, in the presence and in the absence of the test compound.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: September 20, 2022
    Assignee: TAKASAGO INTERNATIONAL CORPORATION
    Inventors: Jonathan Warr, Marcel Winnig
  • Patent number: 11434377
    Abstract: Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I) or a stereoisomer, tautomer or salt thereof, wherein R1, R2, R3, R4, R5, L1, L2, L3, L4, L5, A, M, m and n are as defined herein. Methods associated with preparation and use of such compounds are also provided.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: September 6, 2022
    Assignee: Sony Corporation
    Inventors: Tracy Matray, Sharat Singh, Michael VanBrunt
  • Patent number: 11422128
    Abstract: Regardless of the type of specimen, such as a serum or heparinized plasma containing different anticoagulants, which are widely used in general, when a substance to be measured (for example, sIL-2R) in a biological sample is immunologically detected, a measuring method and a kit capable of stably obtaining with high accuracy, unaffected by interfering substances in the specimen, are provided. An immunocomplex between the substance to be measured and an antibody that specifically binds to the substance to be measured is formed in the presence of a sulfated polysaccharide. The kit comprises an antibody that specifically binds to the substance to be measured, and a buffer containing a sulfated polysaccharide.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: August 23, 2022
    Assignee: LSI MEDIENCE CORPORATION
    Inventors: Ryuhei Shimizu, Keiichi Shoji, Xu Zhang
  • Patent number: 11415579
    Abstract: The present invention relates to a method of measuring the rate of reaction between a target molecule and a ligand candidate, ligands of interest identified according to this method and drugs developed from such ligands. The present invention also relates to a method of measuring the rate of reaction between a thiol and a molecule capable of reacting with said thiol.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: August 16, 2022
    Assignee: Imperial College Innovations Ltd.
    Inventors: David Julian Mann, Gregory Benedict Craven, Stefan Matthies, Alan Armstrong
  • Patent number: 11413683
    Abstract: The present invention relates to the field of industrial processes for measuring sugars and starch in cells and concerns the process of functionalising synthesized gold nanoparticles functionalized with polymer ligands, for the selective measurement of sucrose or starch in intracellular fluid. Also disclosed is a nanocompound for measuring the concentration of sucrose or starch in intracellular fluid, which contains synthesized gold nanoparticles functionalized with polymer ligands.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: August 16, 2022
    Assignees: PONTIFICIA UNIVERSIDAD JAVERIANA, CENTRO INTERNACIONAL DE AGRICULTURA TROPICAL—CIAT
    Inventors: Andres Jaramillo Botero, Diana Patricia Hermith Ramirez, Pedro Hernandez
  • Patent number: 11402372
    Abstract: A method of screening a cereblon modifying compound for treating a disease or disorder, comprising: obtaining a sample; determining a first protein level of SALL4; administering the cereblon modifying compound to the sample; determining a second protein level of SALL4; comparing the first level and the second protein level of SALL4 to determine if the cereblon modifying compound induces degradation of SALL4; and selecting the cereblon modifying compound that does not induce degradation of SALL4.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: August 2, 2022
    Assignee: CELGENE CORPORATION
    Inventors: Mary Matyskiela, Philip Chamberlain, Suzana Sturlini Couto, Katherine Stamp, Philip J. Sherratt, Gang Lu, Julia Hui
  • Patent number: 11402395
    Abstract: Compounds and methods for use in detecting gabapentin in a sample suspected of containing gabapentin are disclosed. Gabapentin derivatives are used to produce gabapentin conjugates. A gabapentin-immunogenic carrier conjugate may be used as an immunogen for the preparation of an anti-gabapentin antibody. A gabapentin-detectable label may be used in a signal producing system in gabapentin assays.
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: August 2, 2022
    Assignee: ARK Diagnostics, Inc.
    Inventors: Johnny Jose Valdez, Byung Sook Moon, Michael Kevin Helms, Alejandro A. Orozco
  • Patent number: 11396522
    Abstract: The invention provides fluorescence-quenched substrates of exo-glycosidase enzymes. The invention also provides methods for imaging exo-glycosidase enzymes activity within cells.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: July 26, 2022
    Assignee: ALECTOS THERAPEUTICS INC.
    Inventors: David J. Vocadlo, Samy Cecioni, Roger Ashmus
  • Patent number: 11385246
    Abstract: Disclosed is an antibody which binds to paliperidone, which can be used to detect paliperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of paliperidone, including multiplex detection of aripiprazole, quetiapine, olanzapine, and risperidone/paliperidone in a single lateral flow assay device.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: July 12, 2022
    Assignee: Saladax Biomedical Inc.
    Inventors: Eric Hryhorenko, Banumathi Sankaran, Thomas R. DeCory, Theresa Tubbs, Linda Colt, Maarten Vliegen, Pieter Rik Haspeslagh
  • Patent number: 11365210
    Abstract: Disclosed herein are novel quinone methide analog precursors and embodiments of a method and a kit of using the same for detecting one or more targets in a biological sample. The method of detection comprises contacting the sample with a detection probe, then contacting the sample with a labeling conjugate that comprises an enzyme. The enzyme interacts with a quinone methide analog precursor comprising a detectable label, forming a reactive quinone methide analog, which binds to the biological sample proximally to or directly on the target. The detectable label is then detected. In some embodiments, multiple targets can be detected by multiple quinone methide analog precursors interacting with different enzymes without the need for an enzyme deactivation step.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: June 21, 2022
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Christopher Bieniarz, Julia Ashworth-Sharpe, Brian D. Kelly, Nathan Polaske
  • Patent number: 11360095
    Abstract: The present invention relates to a set of two or more mass labels, wherein each mass label comprises the formula: X-L-M-Re wherein X is a reporter moiety having an exact mass, L is a bond cleavable by collision in a mass spectrometer, M is a mass modifier, and Re is a) a reactive functionality for attaching the mass label to an analyte or b) the analyte, wherein each mass label in the set has an integer mass, wherein each mass label in the set has the same integer mass, and wherein the set comprises two or more subsets of mass labels, each subset comprising one, two or more mass labels, and wherein, when the subset comprises two or more mass labels, the exact mass of the reporter moiety X of each mass label in the subset is different from the exact mass of the reporter moiety X of the mass labels in the same subset and in all other subsets, and wherein each mass label is distinguishable by mass spectrometry.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: June 14, 2022
    Assignee: ELECTROPHORETICS LIMITED
    Inventor: Andrew Hugin Thompson
  • Patent number: 11359185
    Abstract: Antibody/signal-generating moiety conjugates are disclosed that include an antibody covalently linked to a signal-generating moiety through a heterobifunctional polyalkyleneglycol linker. The disclosed conjugates show exceptional signal-generation in immunohistochemical and in situ hybridization assays on tissue sections and cytology samples. In one embodiment, enzyme-metallographic detection of nucleic acid sequences with hapten-labeled probes can be accomplished using the disclosed conjugates as a primary antibody without amplification.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: June 14, 2022
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Christopher Bieniarz, Jerome W Kosmeder, Mark Lefever, Casey A Kernag, Julia Ashworth-Sharpe, Jennifer Wong
  • Patent number: 11353463
    Abstract: Chemoselective conjugation is achieved through redox reactivity by reacting an N-transfer oxidant with a thioether substrate in a redox reaction in an aqueous environment to form a conjugation product. In embodiments, Redox-Activated Chemical Tagging (ReACT) strategies for methionine-based protein functionalization. Oxaziridine (Ox) compounds serve as oxidant-mediated reagents for direct functionalization by converting methionine to the corresponding sulfimide conjugation product.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: June 7, 2022
    Assignee: The Regents of the University of California
    Inventors: ShiXian Lin, XiaoYu Yang, F. Dean Toste, Christopher J. Chang
  • Patent number: 11345719
    Abstract: Disclosed herein are caged haptens and caged hapten-antibody conjugates useful for enabling the detection of targets located proximally to each other in a sample.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: May 31, 2022
    Assignee: Vetana Medical Systems, Inc.
    Inventors: Yuri Belosludtsev, Traci D. DeGeer, Wendy J. French, Junshan Hao, Brian D. Kelly, Adrian E. Murillo, Nathan W. Polaske
  • Patent number: 11340233
    Abstract: The present invention relates to a new method for capturing and analysing antibody-drug conjugates (ADCs) in biological samples, such as e.g., serum. Methods for analysing the structure of an antibody-drug conjugate (ADC) in a biological sample and methods for assessing the stability of an ADC are also provided.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: May 24, 2022
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Christine Klinguer-Hamour, Marie-Claire Janin-Bussat
  • Patent number: 11340235
    Abstract: The invention relates to a method for binding or capturing autoantibodies directed to various Glycoprotein 2 (GP2) isoforms. In particular the invention provides an in vitro method for the diagnosis of an autoimmune disorder by the detection of autoantibodies that bind one or more isoforms of GP2. The invention is characterized by the provision of multiple isoforms of GP2 as autoantibody targets and encompasses the practical utilization of the finding that the isoform specificity of anti-GP2 autoantibodies enables determination of particular autoimmune diseases. The invention also provides a system and kit developed for carrying out the claimed method. The present invention is useful for determining whether a sample from an individual comprises autoantibodies associated with an autoimmune disease, and for differentiating between multiple autoimmune diseases that exhibit similar symptoms, such as Celiac disease (CeD), Crohn's disease (CD), primary sclerosing cholangitis (PSC), and/or ulcerative colitis (UC).
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: May 24, 2022
    Assignee: GA GENERIC ASSAYS GMBH
    Inventor: Dirk Roggenbuck